Document and Entity Information
Document and Entity Information - shares | 9 Months Ended | |
Jan. 27, 2018 | Mar. 01, 2018 | |
Document And Entity Information [Abstract] | ||
Document Type | 10-Q | |
Amendment Flag | false | |
Document Period End Date | Jan. 27, 2018 | |
Document Fiscal Year Focus | 2,018 | |
Document Fiscal Period Focus | Q3 | |
Trading Symbol | PDCO | |
Entity Registrant Name | PATTERSON COMPANIES, INC. | |
Entity Central Index Key | 891,024 | |
Current Fiscal Year End Date | --04-28 | |
Entity Filer Category | Large Accelerated Filer | |
Entity Common Stock, Shares Outstanding | 94,634,000 |
CONDENSED CONSOLIDATED BALANCE
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Jan. 27, 2018 | Apr. 29, 2017 |
Current assets: | ||
Cash and cash equivalents | $ 118,005 | $ 94,959 |
Receivables, net of allowance for doubtful accounts | 863,455 | 884,803 |
Inventory | 882,018 | 711,903 |
Prepaid expenses and other current assets | 116,310 | 111,928 |
Total current assets | 1,979,788 | 1,803,593 |
Property and equipment, net | 287,439 | 298,452 |
Long-term receivables, net | 121,675 | 101,529 |
Goodwill | 816,808 | 813,547 |
Identifiable intangibles, net | 399,566 | 425,436 |
Other | 69,082 | 65,356 |
Total assets | 3,674,358 | 3,507,913 |
Current liabilities: | ||
Accounts payable | 654,792 | 616,859 |
Accrued payroll expense | 53,156 | 56,881 |
Other accrued liabilities | 138,384 | 156,437 |
Current maturities of long-term debt | 74,754 | 14,754 |
Borrowings on revolving credit | 179,000 | 59,000 |
Total current liabilities | 1,100,086 | 903,931 |
Long-term debt | 931,419 | 998,272 |
Other non-current liabilities | 179,863 | 211,277 |
Total liabilities | 2,211,368 | 2,113,480 |
Stockholders’ equity: | ||
Common stock | 947 | 966 |
Additional paid-in capital | 95,866 | 72,973 |
Accumulated other comprehensive loss | (66,763) | (92,669) |
Retained earnings | 1,501,011 | 1,481,234 |
Unearned ESOP shares | (68,071) | (68,071) |
Total stockholders’ equity | 1,462,990 | 1,394,433 |
Total liabilities and stockholders’ equity | $ 3,674,358 | $ 3,507,913 |
CONDENSED CONSOLIDATED STATEMEN
CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND OTHER COMPREHENSIVE INCOME - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Jan. 27, 2018 | Jan. 28, 2017 | Jan. 27, 2018 | Jan. 28, 2017 | |
Income Statement [Abstract] | ||||
Net sales | $ 1,375,222 | $ 1,397,418 | $ 4,065,074 | $ 4,148,095 |
Cost of sales | 1,080,486 | 1,067,657 | 3,155,547 | 3,182,196 |
Gross profit | 294,736 | 329,761 | 909,527 | 965,899 |
Operating expenses | 244,690 | 283,207 | 730,889 | 774,126 |
Operating income from continuing operations | 50,046 | 46,554 | 178,638 | 191,773 |
Other income (expense): | ||||
Other income, net | 2,096 | 994 | 4,768 | 4,980 |
Interest expense | (11,783) | (11,400) | (34,454) | (31,659) |
Income from continuing operations before taxes | 40,359 | 36,148 | 148,952 | 165,094 |
Income tax expense (benefit) | (68,596) | 8,379 | (31,094) | 52,663 |
Net income from continuing operations | 108,955 | 27,769 | 180,046 | 112,431 |
Net loss from discontinued operations | 0 | (3,229) | 0 | (3,229) |
Net income | $ 108,955 | $ 24,540 | $ 180,046 | $ 109,202 |
Basic earnings (loss) per share: | ||||
Continuing operations (in USD per share) | $ 1.18 | $ 0.29 | $ 1.94 | $ 1.18 |
Discontinued operations (in USD per share) | 0 | (0.03) | 0 | (0.03) |
Net basic earnings per share (in USD per share) | 1.18 | 0.26 | 1.94 | 1.15 |
Diluted earnings (loss) per share: | ||||
Continuing operations (in USD per share) | 1.18 | 0.29 | 1.93 | 1.17 |
Discontinued operations (in USD per share) | 0 | (0.03) | 0 | (0.03) |
Net diluted earning per share (in USD per share) | $ 1.18 | $ 0.26 | $ 1.93 | $ 1.14 |
Weighted average shares: | ||||
Basic (in shares) | 91,949 | 94,737 | 92,674 | 95,252 |
Diluted (in shares) | 92,609 | 95,359 | 93,323 | 95,915 |
Dividends declared per common share (in USD per share) | $ 0.26000 | $ 0.24 | $ 0.78 | $ 0.72 |
Comprehensive income | ||||
Net income | $ 108,955 | $ 24,540 | $ 180,046 | $ 109,202 |
Foreign currency translation gain (loss) | 16,475 | 6,082 | 24,594 | (28,176) |
Cash flow hedges, net of tax | 437 | 437 | 1,312 | 1,307 |
Comprehensive income | $ 125,867 | $ 31,059 | $ 205,952 | $ 82,333 |
CONDENSED CONSOLIDATED STATEME4
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands | 9 Months Ended | |
Jan. 27, 2018 | Jan. 28, 2017 | |
Operating activities: | ||
Net income | $ 180,046 | $ 109,202 |
Net loss from discontinued operations | 0 | (3,229) |
Net income from continuing operations | 180,046 | 112,431 |
Adjustments to reconcile net income from continuing operations to net cash provided by (used in) operating activities: | ||
Depreciation | 33,672 | 29,037 |
Amortization | 29,115 | 34,019 |
Intangible asset impairment | 0 | 36,312 |
Bad debt expense | 4,471 | 1,013 |
Non-cash employee compensation | 22,999 | 17,254 |
Deferred income taxes | (38,299) | (7,220) |
Change in assets and liabilities, net of acquired | (191,991) | (232,257) |
Net cash provided by (used in) operating activities- continuing operations | 40,013 | (9,411) |
Net cash used in operating activities- discontinued operations | 0 | (3,229) |
Net cash provided by (used in) operating activities | 40,013 | (12,640) |
Investing activities: | ||
Additions to property and equipment | (28,239) | (37,457) |
Collection of deferred purchase price receivables | 37,068 | 38,964 |
Other investing activities | 10,600 | (3,095) |
Net cash provided by (used in) investing activities- continuing operations | 19,429 | (1,588) |
Net cash provided by investing activities- discontinued operations | 0 | 0 |
Net cash provided by (used in) investing activities | 19,429 | (1,588) |
Financing activities: | ||
Dividends paid | (74,641) | (70,947) |
Repurchases of common stock | (87,500) | (84,651) |
Debt amendment costs | 0 | (1,266) |
Retirement of long-term debt | (7,377) | (22,550) |
Draw on revolver | 120,000 | 178,000 |
Other financing activities | 7,546 | 5,495 |
Net cash provided by (used in) financing activities | (41,972) | 4,081 |
Effect of exchange rate changes on cash | 5,576 | (5,567) |
Net change in cash and cash equivalents | 23,046 | (15,714) |
Cash and cash equivalents at beginning of period | 94,959 | 137,453 |
Cash and cash equivalents at end of period | $ 118,005 | $ 121,739 |
General
General | 9 Months Ended |
Jan. 27, 2018 | |
Accounting Policies [Abstract] | |
General | General Basis of Presentation In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments necessary to present fairly the financial position of Patterson Companies, Inc. (referred to herein as "Patterson" or in the first person notations "we," "our," and "us") as of January 27, 2018 , and our results of operations and cash flows for the periods ended January 27, 2018 and January 28, 2017 . Such adjustments are of a normal recurring nature. The results of operations for the periods ended January 27, 2018 and January 28, 2017 are not necessarily indicative of the results to be expected for the full year. These financial statements should be read in conjunction with the financial statements included in our 2017 Annual Report on Form 10-K filed on June 28, 2017. The unaudited condensed consolidated financial statements include the assets and liabilities of PDC Funding Company, LLC ("PDC Funding") and PDC Funding Company II, LLC ("PDC Funding II"), which are our wholly owned subsidiaries and separate legal entities formed under Minnesota law. PDC Funding and PDC Funding II are fully consolidated special purpose entities established to sell customer installment sale contracts to outside financial institutions in the normal course of their business. The assets of PDC Funding and PDC Funding II would be available first and foremost to satisfy the claims of its creditors. There are no known creditors of PDC Funding or PDC Funding II. Fiscal Year End We operate with a 52-53 week accounting convention with our fiscal year ending on the last Saturday in April. The third quarter of fiscal 2018 and 2017 represents the 13 weeks ended January 27, 2018 and the 13 weeks ended January 28, 2017 , respectively. The nine months ended January 27, 2018 and January 28, 2017 each included 39 weeks. Fiscal 2018 will include 52 weeks and fiscal 2017 included 52 weeks. Comprehensive Income Comprehensive income is computed as net income including certain other items that are recorded directly to stockholders’ equity. Significant items included in comprehensive income are foreign currency translation adjustments and the effective portion of cash flow hedges, net of tax. Foreign currency translation adjustments do not include a provision for income tax because earnings from foreign operations are considered to be indefinitely reinvested outside the U.S. The income tax expense related to cash flow hedges was $265 and $265 for the three months ended January 27, 2018 and January 28, 2017 , respectively. The income tax expense related to cash flow hedges was $795 and $792 for the nine months ended January 27, 2018 and January 28, 2017 , respectively. Earnings Per Share The following table sets forth the computation of the weighted average shares outstanding used to calculate basic and diluted earnings per share ("EPS"): Three Months Ended Nine Months Ended January 27, January 28, January 27, January 28, Denominator for basic earnings per share – weighted average shares 91,949 94,737 92,674 95,252 Effect of dilutive securities – stock options, restricted stock and stock purchase plans 660 622 649 663 Denominator for diluted earnings per share – weighted average shares 92,609 95,359 93,323 95,915 Potentially dilutive securities representing 1,568 and 1,354 shares for the three and nine months ended January 27, 2018 , respectively, and 1,499 and 1,261 shares for the three and nine months ended January 28, 2017 , respectively, were excluded from the calculation of diluted earnings per share because their effects were anti-dilutive. Recently Issued Accounting Pronouncements In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2014-09, "Revenue from Contracts with Customers (Topic 606)". ASU No. 2014-09 supersedes the revenue recognition requirements in "Revenue Recognition (Topic 605)," and requires entities to recognize revenue in a way that depicts the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In July 2015, the FASB deferred the effective date of this pronouncement by one year to December 15, 2017 for annual reporting periods beginning after that date. Companies may use either a full retrospective or a modified retrospective approach to adopt the standard. We plan to adopt the new guidance in the first quarter of fiscal 2019 and are currently evaluating the standard, including the method we will use for adoption and the effect it will have on our financial statements. We do not expect the standard to materially affect our consolidated net earnings, financial position, or cash flows. We are currently evaluating the new standard as it relates to certain sales transactions in which products are shipped directly from the vendor to our customers. We currently report these sales on a gross basis, and are evaluating if we will be required to report these sales on a net basis. Such sales represent approximately 2% of our consolidated net sales. Any change to net presentation would not impact gross margin or earnings. In July 2015, the FASB issued ASU No. 2015-11, "Inventory (Topic 330), Simplifying the Measurement of Inventory." ASU 2015-11 requires inventory measured using any method other than LIFO or the retail inventory method to be subsequently measured at the lower of cost or net realizable value, rather than at the lower of cost or market. Subsequent measurement of inventory using the LIFO and retail inventory method is unchanged. During the first quarter of fiscal 2018, we adopted ASU No. 2015-11 and it had no material impact to the condensed consolidated financial statements. In January 2016, the FASB issued ASU No. 2016-01, "Financial Instruments- Recognition and Measurement of Financial Assets and Financial Liabilities (Subtopic 825-10)", which amends certain aspects of recognition, measurement, presentation and disclosure of financial instruments, including the requirement to measure certain equity investments at fair value with changes in fair value recognized in net income. We are required to adopt the ASU No. 2016-01 in the first quarter of fiscal 2019. We are evaluating the impact of adopting this pronouncement. In February 2016, the FASB issued ASU No. 2016-02, "Leases (Topic 842)," which requires lessees to recognize assets and liabilities on the balance sheet for the rights and obligations created by most leases, as well as requires additional qualitative and quantitative disclosures. We are required to adopt ASU 2016-02 in the first quarter of fiscal 2020, with early adoption permitted. We plan to adopt the new guidance in the first quarter of fiscal 2020 and are currently evaluating the impact of adopting this pronouncement. In February 2018, the FASB issued ASU No. 2018-02, "Income Statement-Reporting Comprehensive Income (Topic 220) Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income," which will allow a reclassification from accumulated other comprehensive income to retained earnings for the tax effects that are stranded in accumulated other comprehensive income as a result of tax reform. This standard also requires certain disclosures about stranded tax effects. We are required to adopt ASU No. 2018-02 in the first quarter of fiscal 2020, with early adoption permitted and apply it either in the period of adoption or retrospectively to each period in which the income tax effects of the tax reform related to items in accumulated other comprehensive income are recognized. We are currently evaluating the impact of adopting this pronouncement. |
Customer Financing
Customer Financing | 9 Months Ended |
Jan. 27, 2018 | |
Receivables [Abstract] | |
Customer Financing | Customer Financing As a convenience to our customers, we offer several different financing alternatives, including a third party program and a Patterson-sponsored program. For the third party program, we act as a facilitator between the customer and the third party financing entity with no on-going involvement in the financing transaction. Under the Patterson-sponsored program, equipment purchased by creditworthy customers may be financed up to a maximum of $1,000 . We generally sell our customers’ financing contracts to outside financial institutions in the normal course of our business. These financing arrangements are accounted for as a sale of assets under the provisions of ASC 860, Transfers and Servicing . We currently have two arrangements under which we sell these contracts. First, we operate under an agreement to sell a portion of our equipment finance contracts to commercial paper conduits with The Bank of Tokyo-Mitsubishi UFJ, Ltd. ("BTMU") serving as the agent. We utilize PDC Funding to fulfill a requirement of participating in the commercial paper conduit. We receive the proceeds of the contracts upon sale to BTMU. At least 9.5% of the proceeds are held by the conduit as security against eventual performance of the portfolio. This percentage can be greater and is based upon certain ratios defined in the agreement with BTMU. The capacity under the agreement with BTMU at January 27, 2018 was $575,000 . Second, we maintain an agreement with Fifth Third Bank ("Fifth Third") whereby Fifth Third purchases customers’ financing contracts. PDC Funding II sells its financing contracts to Fifth Third. We receive the proceeds of the contracts upon sale to Fifth Third. At least 11.0% of the proceeds are held by the conduit as security against eventual performance of the portfolio. This percentage can be greater and is based upon certain ratios defined in the agreement with Fifth Third. The capacity under the agreement with Fifth Third at January 27, 2018 was $100,000 . We service the financing contracts under both arrangements, for which we are paid a servicing fee. The servicing fees we receive are considered adequate compensation for services rendered. Accordingly, no servicing asset or liability has been recorded. The portion of the purchase price for the receivables held by the conduits is deemed a deferred purchase price receivable, which is paid to the applicable special purpose entity as payments on the customers’ financing contracts are collected by Patterson from customers. The difference between the carrying amount of the receivables sold under these programs and the sum of the cash and fair value of the deferred purchase price receivables received at time of transfer is recognized as a gain on sale of the related receivables and recorded in net sales in the condensed consolidated statements of income and other comprehensive income. Expenses incurred related to customer financing activities are recorded in operating expenses in our condensed consolidated statements of income and other comprehensive income. During the three months ended January 27, 2018 and January 28, 2017 , we sold $45,361 and $106,272 of contracts under these arrangements, respectively. During the nine months ended January 27, 2018 and January 28, 2017 , we sold $197,072 and $278,529 of contracts under these arrangements, respectively. In net sales in the condensed consolidated statements of income and other comprehensive income, we recorded a loss of $1,688 during the three months ended January 27, 2018 , and a gain of $2,450 during the three months ended January 28, 2017 related to these contracts sold. In net sales in the condensed consolidated statements of income and other comprehensive income, we recorded a gain of $8,539 and $16,966 during the nine months ended January 27, 2018 and January 28, 2017 , respectively, related to these contracts sold. Included in cash and cash equivalents in the condensed consolidated balance sheets are $36,009 and $17,902 as of January 27, 2018 and April 29, 2017 , respectively, which represent cash collected from previously sold customer financing contracts that have not yet been settled. Included in current receivables in the condensed consolidated balance sheets are $114,521 , net of unearned income of $0 , and $124,098 , net of unearned income of $940 , as of January 27, 2018 and April 29, 2017 , respectively, of finance contracts we have not yet sold. A total of $581,291 of finance contracts receivable sold under the arrangements was outstanding at January 27, 2018 . The deferred purchase price receivable under the arrangements was $137,054 and $119,798 as of January 27, 2018 and April 29, 2017 , respectively. Since the internal financing program began in 1994, bad debt write-offs have amounted to less than 1% of the loans originated. The arrangements require us to maintain a minimum current ratio and maximum leverage ratio. We were in compliance with those covenants at January 27, 2018 . |
Derivative Financial Instrument
Derivative Financial Instruments | 9 Months Ended |
Jan. 27, 2018 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |
Derivative Financial Instruments | Derivative Financial Instruments We are a party to certain offsetting and identical interest rate cap agreements entered into to fulfill certain covenants of the equipment finance contract sale agreements. The interest rate cap agreements also provide a credit enhancement feature for the financing contracts sold by PDC Funding and PDC Funding II to the commercial paper conduit. The interest rate cap agreements are canceled and new agreements are entered into periodically to maintain consistency with the dollar maximum of the sale agreements and the maturity of the underlying financing contracts. As of January 27, 2018 , PDC Funding had purchased an interest rate cap from a bank with a notional amount of $575,000 and a maturity date of July 2025. We sold an identical interest rate cap to the same bank. As of January 27, 2018 , PDC Funding II had purchased an interest rate cap from a bank with a notional amount of $100,000 and a maturity date of July 2025. We sold an identical interest rate cap to the same bank. These interest rate cap agreements do not qualify for hedge accounting treatment and, accordingly, we record the fair value of the agreements as an asset or liability and the change as income or expense during the period in which the change occurs. In March 2008, we entered into two forward starting interest rate swap agreements, each with notional amounts of $100,000 and accounted for as cash flow hedges, to hedge interest rate fluctuations in anticipation of the issuance of the senior notes due fiscal 2015 and fiscal 2018 . Upon issuance of the hedged debt, we settled the forward starting interest rate swap agreements and recorded a $1,000 increase, net of income taxes, to other comprehensive income (loss), which is being amortized as a reduction to interest expense over the life of the related debt. In January 2014, we entered into a forward interest rate swap agreement with a notional amount of $250,000 and accounted for as cash flow hedge, to hedge interest rate fluctuations in anticipation of refinancing the 5.17% senior notes due March 25, 2015 . These notes were repaid on March 25, 2015 and replaced with new $250,000 3.48% senior notes due March 24, 2025 . A cash payment of $29,003 was made in March 2015 to settle the interest rate swap. This amount is recorded in other comprehensive income (loss), net of tax, and is recognized as interest expense over the life of the related debt. The following presents the fair value of derivative instruments included in the condensed consolidated balance sheets: Derivative type Classification January 27, 2018 April 29, 2017 Assets: Interest rate cap agreements Other noncurrent assets $ 1,061 $ 1,188 Liabilities: Interest rate cap agreements Other noncurrent liabilities 1,061 1,188 The following table presents the pre-tax effect of derivative instruments in cash flow hedging relationships on the condensed consolidated statements of income and other comprehensive income ("OCI"): Amount of Gain (Loss) Reclassified from Accumulated Other Comprehensive Loss into Income (Effective Portion) Three Months Ended Nine Months Ended Derivatives in cash flow hedging relationships Income statement location January 27, 2018 January 28, 2017 January 27, 2018 January 28, 2017 Interest rate swap Interest expense $ (702 ) $ (702 ) $ (2,107 ) $ (2,099 ) We recorded no effective portion of gains or losses on derivative instruments in cash flow hedging relationships in OCI during the current period. We recorded no ineffectiveness during the three and nine month periods ended January 27, 2018 and January 28, 2017 . As of January 27, 2018 , the estimated pre-tax portion of accumulated other comprehensive loss that is expected to be reclassified into earnings over the next twelve months is $2,885 , which will be recorded as an increase to interest expense. |
Fair Value Measurements
Fair Value Measurements | 9 Months Ended |
Jan. 27, 2018 | |
Fair Value Disclosures [Abstract] | |
Fair Value Measurements | Fair Value Measurements Fair value is the price at which an asset could be exchanged in a current transaction between knowledgeable, willing parties. The fair value hierarchy of measurements is categorized into one of three levels based on the lowest level of significant input used: Level 1 - Quoted prices in active markets for identical assets and liabilities at the measurement date. Level 2 - Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data. Level 3 - Unobservable inputs for which there is little or no market data available. These inputs reflect management’s assumptions of what market participants would use in pricing the asset or liability. Our hierarchy for assets and liabilities measured at fair value on a recurring basis is as follows: January 27, 2018 Total Level 1 Level 2 Level 3 Assets: Cash equivalents $ 3,401 $ 3,401 $ — $ — Deferred purchase price receivable 137,054 — — 137,054 Derivative instruments 1,061 — 1,061 — Total assets $ 141,516 $ 3,401 $ 1,061 $ 137,054 Liabilities: Derivative instruments $ 1,061 $ — $ 1,061 $ — April 29, 2017 Total Level 1 Level 2 Level 3 Assets: Cash equivalents $ 6,798 $ 6,798 $ — $ — Deferred purchase price receivable 119,798 — — 119,798 Derivative instruments 1,188 — 1,188 — Total assets $ 127,784 $ 6,798 $ 1,188 $ 119,798 Liabilities: Derivative instruments $ 1,188 $ — $ 1,188 $ — Cash equivalents – We value cash equivalents at their current market rates. The carrying value of cash equivalents approximates fair value and maturities are less than three months. Deferred purchase price receivable – We value the deferred purchase price receivable based on a discounted cash flow analysis using unobservable inputs, which include a forward yield curve, the estimated timing of payments and the credit quality of the underlying creditor. Significant changes in any of the significant unobservable inputs in isolation would not result in a materially different fair value estimate. The interrelationship between these inputs is insignificant. Derivative instruments – Our derivative instruments consist of interest rate cap agreements and interest rate swaps. These instruments are valued using inputs such as interest rates and credit spreads. Certain assets are measured at fair value on a non-recurring basis. These assets are not measured at fair value on an ongoing basis, but are subject to fair value adjustments under certain circumstances, such as when there is evidence of impairment. There were no fair value adjustments to such assets during the nine month period ended January 27, 2018 . During the nine month period ended January 28, 2017 , we recorded a non-cash impairment charge of $36,312 related to a distribution agreement intangible asset. Refer to Note 6 for more information. Our debt is not measured at fair value in the condensed consolidated balance sheets. The estimated fair value of our debt as of January 27, 2018 and April 29, 2017 was $1,013,300 and $1,025,761 , respectively, as compared to a carrying value of $1,006,173 and $1,013,026 at January 27, 2018 and April 29, 2017 , respectively. The fair value of debt was measured using a discounted cash flow analysis based on expected market based yields (i.e., level 2 inputs). The carrying amounts of receivables, net of allowances, accounts payable, and certain accrued and other current liabilities approximated fair value at January 27, 2018 and April 29, 2017 . |
Income Taxes
Income Taxes | 9 Months Ended |
Jan. 27, 2018 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | Income Taxes The effective income tax rate for the three months ended January 27, 2018 was (170.0)% compared to 23.2% for the three months ended January 28, 2017 , and for the nine months ended January 27, 2018 was (20.9)% compared to 31.9% for the nine months ended January 28, 2017 . The tax benefit for the three and nine months ended January 27, 2018 was primarily due to the impact of the Tax Cuts and Jobs Act ("Tax Act"), enacted on December 22, 2017 by the U.S. government. The Tax Act significantly revises the future ongoing U.S. federal corporate income tax by, among other things, lowering U.S. federal corporate tax rates and implementing a territorial tax system. Effective January 1, 2018, the Tax Act reduced the U.S. federal corporate tax rate from 35.0% to 21.0% . For our fiscal year ending April 28, 2018, we will utilize a blended rate of approximately 30.5% . For the quarter ended January 27, 2018, these impacts resulted in a provisional discrete net tax benefit of $77,256 , which included provisional amounts of $81,206 of tax benefit on U.S. deferred tax assets and liabilities and $3,950 of tax expense for a one-time transition tax on unremitted foreign earnings. The legislative changes included in the Tax Act are broad and complex. We determined that the transition tax on unremitted foreign earnings is provisional because various components of the computation are unknown as of January 27, 2018. In addition, we determined that the impact of the U.S. federal corporate income tax rate change on the U.S. deferred tax assets and liabilities is provisional because the amount cannot be calculated until the underlying timing differences are known rather than estimated. Given the Tax Act’s significant changes and potential opportunities to repatriate cash tax free, we are in the process of evaluating our current indefinite assertions with regard to cash and earnings that have been subjected to the transition tax. We continue to apply ASC 740 based on the provisions of the tax law that were in effect immediately prior to the enactment of the Tax Act. With regard to unremitted earnings of foreign subsidiaries that have not been previously taxed, we do not currently provide for U.S. taxes since we intend to invest such undistributed earnings indefinitely outside of the U.S. We continue to review the anticipated impacts of the global intangible low taxed income (“GILTI”) and base erosion and anti-abuse tax (“BEAT”) provisions which are not effective until fiscal year 2019. We have not recorded any impact associated with either GILTI or BEAT in the tax rate for the three months ended January 27, 2018. The final transition impacts of the Tax Act may differ from the above estimate, possibly materially, due to, among other things, changes in interpretations of the Tax Act, any federal and/or state legislative action to address questions that arise because of the Tax Act, any changes in accounting standards for income taxes or related interpretations in response to the Tax Act, or any updates or changes to estimates we have utilized to calculate the transition impacts, including impacts from changes to current year earnings estimates and foreign exchange rates of foreign subsidiaries. The Securities and Exchange Commission has issued rules that will allow for a measurement period of up to one year after the enactment date of the Tax Act to finalize the recording of the related tax impacts. |
Intangible Asset Impairment
Intangible Asset Impairment | 9 Months Ended |
Jan. 27, 2018 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Intangible Asset Impairment | Intangible Asset Impairment In 2006, we extended our exclusive North American distribution relationship with Sirona Dental Systems for Sirona’s CEREC 3D dental restorative system. At that time, we paid a $100,000 distribution fee to extend the existing exclusive relationship for at least a 10 -year period beginning in 2007. This distribution fee was accounted for as an intangible asset and amortized since 2007. Based on our November 2016 decision not to extend sales exclusivity for the full Sirona portfolio of products, we recorded a pre-tax non-cash impairment charge of $36,312 in our Dental segment in the third quarter of fiscal 2017, related to the distribution fee associated with the CEREC product component of this arrangement. This charge was recorded within operating expenses in the condensed consolidated statements of income and other comprehensive income. |
Segment Reporting
Segment Reporting | 9 Months Ended |
Jan. 27, 2018 | |
Segment Reporting [Abstract] | |
Segment Reporting | Segment Reporting We present three reportable segments: Dental, Animal Health and Corporate. Dental and Animal Health are strategic business units that offer similar products and services to different customer bases. Dental provides a virtually complete range of consumable dental products, equipment and software, turnkey digital solutions and value-added services to dentists, dental laboratories, institutions, and other healthcare professionals throughout North America. Animal Health is a leading, full-line distributor in North America and the U.K. of animal health products, services and technologies to both the production-animal and companion-pet markets. Our Corporate segment is comprised of general and administrative expenses, including home office support costs in areas such as information technology, finance, legal, human resources and facilities. In addition, customer financing and other miscellaneous sales are reported within Corporate results. Corporate assets consist primarily of cash and cash equivalents, accounts receivable, property and equipment and long-term receivables. We evaluate segment performance based on operating income. The costs to operate the fulfillment centers are allocated to the operating units based on the through-put of the unit. The following table presents information about our reportable segments: Three Months Ended Nine Months Ended January 27, January 28, January 27, January 28, Net sales Dental $ 577,877 $ 626,343 $ 1,650,314 $ 1,782,911 Animal Health 794,867 762,577 2,394,586 2,332,354 Corporate 2,478 8,498 20,174 32,830 Consolidated net sales $ 1,375,222 $ 1,397,418 $ 4,065,074 $ 4,148,095 Operating income (loss) from continuing operations Dental $ 58,439 $ 40,018 $ 183,165 $ 177,356 Animal Health 18,037 23,777 57,930 60,460 Corporate (26,430 ) (17,241 ) (62,457 ) (46,043 ) Consolidated operating income from continuing operations $ 50,046 $ 46,554 $ 178,638 $ 191,773 January 27, April 29, Total assets Dental $ 953,273 $ 863,970 Animal Health 2,196,733 2,119,512 Corporate 524,352 524,431 Total assets $ 3,674,358 $ 3,507,913 The following table presents sales information by product for all of our reportable segments: Three Months Ended Nine Months Ended January 27, January 28, January 27, January 28, Net sales Consumable $ 1,074,189 $ 1,064,098 $ 3,270,385 $ 3,252,551 Equipment and software 222,574 249,047 540,860 627,187 Other 78,459 84,273 253,829 268,357 Consolidated net sales $ 1,375,222 $ 1,397,418 $ 4,065,074 $ 4,148,095 |
Accumulated Other Comprehensive
Accumulated Other Comprehensive Loss ("AOCL") | 9 Months Ended |
Jan. 27, 2018 | |
Equity [Abstract] | |
Accumulated Other Comprehensive Loss (AOCL) | Accumulated Other Comprehensive Loss ("AOCL") The following table summarizes the changes in AOCL as of January 27, 2018 : Cash Flow Hedges Currency Translation Adjustment Total AOCL at April 29, 2017 $ (14,989 ) $ (77,680 ) $ (92,669 ) Other comprehensive loss before reclassifications — 24,594 24,594 Amounts reclassified from AOCL 1,312 — 1,312 AOCL at January 27, 2018 $ (13,677 ) $ (53,086 ) $ (66,763 ) The amounts reclassified from AOCL during fiscal 2018 represent gains and losses on cash flow hedges, net of taxes of $795 . The impact to the condensed consolidated statements of income and other comprehensive income was an increase to interest expense of $2,107 . |
Legal Proceedings
Legal Proceedings | 9 Months Ended |
Jan. 27, 2018 | |
Commitments and Contingencies Disclosure [Abstract] | |
Legal Proceedings | Legal Proceedings In September 2015, we were served with a summons and complaint in an action commenced in the U.S. District Court for the Eastern District of New York, entitled SourceOne Dental, Inc. v. Patterson Companies, Inc., Henry Schein, Inc. and Benco Dental Supply Company, Civil Action No. 15-cv-05440-JMA-GRB. SourceOne, as plaintiff, alleges that, through its website, it markets and sells dental supplies and equipment to dentists. SourceOne alleges in the complaint, among other things, that we, along with the defendants Henry Schein and Benco, conspired to eliminate plaintiff as a competitor and to exclude them from the market for the marketing, distribution and sale of dental supplies and equipment in the U.S. and that defendants unlawfully agreed with one another to boycott dentists, manufacturers, and state dental associations that deal with, or considered dealing with, plaintiff. Plaintiff asserts the following claims: (i) unreasonable restraint of trade in violation of state and federal antitrust laws; (ii) tortious interference with prospective business relations; (iii) civil conspiracy; and (iv) aiding and abetting the other defendants’ ongoing tortious and anticompetitive conduct. Plaintiff seeks equitable relief, compensatory and treble damages, jointly and severally, punitive damages, interest, and reasonable costs and expenses, including attorneys’ fees and expert fees. In June 2017, Henry Schein settled with SourceOne and was dismissed from this litigation with prejudice. We are vigorously defending ourselves in this litigation. We do not anticipate that this matter will have a material adverse effect on our financial statements. Beginning in January 2016, purported class action complaints were filed against defendants Henry Schein, Inc., Benco Dental Supply Company and Patterson Companies, Inc. Although there were factual and legal variations among these complaints, each alleged that defendants conspired to foreclose and exclude competitors by boycotting manufacturers, state dental associations, and others that deal with defendants’ competitors. On February 9, 2016, the U.S. District Court for the Eastern District of New York ordered all of these actions, and all other actions filed thereafter asserting substantially similar claims against defendants, consolidated for pre-trial purposes. On February 26, 2016, a consolidated class action complaint was filed by Arnell Prato, D.D.S., P.L.L.C., d/b/a Down to Earth Dental, Evolution Dental Sciences, LLC, Howard M. May, DDS, P.C., Casey Nelson, D.D.S., Jim Peck, D.D.S., Bernard W. Kurek, D.M.D., Larchmont Dental Associates, P.C., and Keith Schwartz, D.M.D., P.A. (collectively, “putative class representatives”) in the U.S. District Court for the Eastern District of New York, entitled In re Dental Supplies Antitrust Litigation, Civil Action No. 1:16-CV-00696-BMC-GRB. Subject to certain exclusions, the putative class representatives seek to represent all persons who purchased dental supplies or equipment in the U.S. directly from any of the defendants, since August 31, 2008. In the consolidated class action complaint, putative class representatives allege a nationwide agreement among Henry Schein, Benco, Patterson and non-party Burkhart Dental Supply Company, Inc. not to compete on price. The consolidated class action complaint asserts a single count under Section 1 of the Sherman Act, and seeks equitable relief, compensatory and treble damages, jointly and severally, interest, and reasonable costs and expenses, including attorneys’ fees and expert fees. While the outcome of litigation is inherently uncertain, we believe the consolidated class action complaint is without merit, and we are vigorously defending ourselves in this litigation. On August 31, 2012, Archer and White Sales, Inc. (“Archer”) filed a complaint against Henry Schein, Inc. as well as Danaher Corporation and its subsidiaries Instrumentarium Dental, Inc., Dental Equipment, LLC, Kavo Dental Technologies, LLC and Dental Imaging Technologies Corporation (collectively, the “Danaher Defendants”) in the United States District Court for the Eastern District of Texas, Civil Action No. 2:12-CV-00572-JRG, styled as an antitrust action under Section 1 of the Sherman Act, and the Texas Free Enterprise Antitrust Act. Archer alleges a conspiracy between Henry Schein, an unnamed company and the Danaher Defendants to terminate or limit Archer’s distribution rights. On August 1, 2017, Archer filed an amended complaint, adding Patterson Companies, Inc. and Benco Dental Supply Company as defendants, and alleging that Henry Schein, Patterson, Benco and non-defendant Burkhart Dental Supply Company, Inc. conspired to pressure and agreed to enlist their common suppliers, including the Danaher Defendants, to join a price-fixing conspiracy and boycott by reducing the distribution territory of, and eventually terminating, Archer. Archer seeks injunctive relief, and damages in an amount to be proved at trial, to be trebled with interest and costs, including attorneys’ fees, jointly and severally. On March 2, 2018, the case was stayed by the United States Supreme Court pending its decision as to whether to review an arbitration issue raised by the Danaher Defendants. We are vigorously defending ourselves in this litigation. We do not anticipate that this matter will have a material adverse effect on our financial statements. On August 17, 2017, IQ Dental Supply, Inc. (“IQ Dental”) filed a complaint in the United States District Court for the Eastern District of New York, entitled IQ Dental Supply, Inc. v. Henry Schein, Inc., Patterson Companies, Inc. and Benco Dental Supply Company, Case No. 2:17-cv-4834. Plaintiff alleges that it is a distributor of dental supplies and equipment, and sells dental products through an online dental distribution platform operated by SourceOne Dental, Inc. IQ Dental alleges, among other things, that defendants conspired to suppress competition from IQ Dental and SourceOne for the marketing, distribution and sale of dental supplies and equipment in the United States, and that defendants unlawfully agreed with one another to boycott dentists, manufacturers and state dental associations that deal with, or considered dealing with, plaintiff and SourceOne. Plaintiff claims that this alleged conduct constitutes unreasonable restraint of trade in violation of Section 1 of the Sherman Act, New York’s Donnelly Act and the New Jersey Antitrust Act, and also makes pendant state law claims for tortious interference with prospective business relations, civil conspiracy and aiding and abetting. Plaintiff seeks injunctive relief, compensatory, treble and punitive damages, jointly and severally, and reasonable costs and expenses, including attorneys’ fees and expert fees. On December 21, 2017, the District Court granted defendants motion to dismiss the complaint with prejudice. Plaintiff has appealed to the Fifth Circuit Court of Appeals. We are vigorously defending ourselves in this litigation. We do not anticipate that this matter will have a material adverse effect on our financial statements. On February 12, 2018, the Federal Trade Commission (“FTC”) issued an administrative complaint entitled In the Matter of Benco Dental Supply Co., Henry Schein, Inc., and Patterson Companies, Inc. Docket No. 9379. The administrative complaint alleges “reason to believe” that Patterson and the other respondents violated Section 5 of the FTC Act, 15 U.S.C. § 45 by conspiring to refuse to offer discounted prices or otherwise negotiate with buying groups seeking to obtain supply agreements on behalf of groups of solo practitioners or small group dental practices. The administrative complaint seeks injunctive relief against Patterson, including an order to cease and desist from the conduct alleged in the complaint and a prohibition from conspiring or agreeing with any competitor or any person to refuse to provide discounts to or compete for the business of any customer. No money damages are sought. We intend to vigorously defend ourselves against the administrative complaint. The administrative complaint provides notice of an October 16, 2018 hearing in front of an Administrative Law Judge of the FTC in Washington, D.C. We do not anticipate this matter will have a material adverse effect on our financial statements. From time to time, we may become a party to other legal proceedings, including, without limitation, product liability claims, intellectual property claims, employment matters, commercial disputes, governmental inquiries and investigations (which may in some cases involve our entering into settlement arrangements or consent decrees), and other matters arising out of the ordinary course of our business. While the results of any legal proceeding cannot be predicted with certainty, in our opinion none of these other pending matters is anticipated to have a material adverse effect on our financial statements. |
General (Policies)
General (Policies) | 9 Months Ended |
Jan. 27, 2018 | |
Accounting Policies [Abstract] | |
Basis of Presentation | Basis of Presentation In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments necessary to present fairly the financial position of Patterson Companies, Inc. (referred to herein as "Patterson" or in the first person notations "we," "our," and "us") as of January 27, 2018 , and our results of operations and cash flows for the periods ended January 27, 2018 and January 28, 2017 . Such adjustments are of a normal recurring nature. The results of operations for the periods ended January 27, 2018 and January 28, 2017 are not necessarily indicative of the results to be expected for the full year. These financial statements should be read in conjunction with the financial statements included in our 2017 Annual Report on Form 10-K filed on June 28, 2017. The unaudited condensed consolidated financial statements include the assets and liabilities of PDC Funding Company, LLC ("PDC Funding") and PDC Funding Company II, LLC ("PDC Funding II"), which are our wholly owned subsidiaries and separate legal entities formed under Minnesota law. PDC Funding and PDC Funding II are fully consolidated special purpose entities established to sell customer installment sale contracts to outside financial institutions in the normal course of their business. The assets of PDC Funding and PDC Funding II would be available first and foremost to satisfy the claims of its creditors. There are no known creditors of PDC Funding or PDC Funding II. |
Fiscal Year End | Fiscal Year End We operate with a 52-53 week accounting convention with our fiscal year ending on the last Saturday in April. The third quarter of fiscal 2018 and 2017 represents the 13 weeks ended January 27, 2018 and the 13 weeks ended January 28, 2017 , respectively. The nine months ended January 27, 2018 and January 28, 2017 each included 39 weeks. Fiscal 2018 will include 52 weeks and fiscal 2017 included 52 weeks. |
Comprehensive Income | Comprehensive Income Comprehensive income is computed as net income including certain other items that are recorded directly to stockholders’ equity. Significant items included in comprehensive income are foreign currency translation adjustments and the effective portion of cash flow hedges, net of tax. Foreign currency translation adjustments do not include a provision for income tax because earnings from foreign operations are considered to be indefinitely reinvested outside the U.S. |
Recently Issued Accounting Pronouncements | Recently Issued Accounting Pronouncements In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2014-09, "Revenue from Contracts with Customers (Topic 606)". ASU No. 2014-09 supersedes the revenue recognition requirements in "Revenue Recognition (Topic 605)," and requires entities to recognize revenue in a way that depicts the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In July 2015, the FASB deferred the effective date of this pronouncement by one year to December 15, 2017 for annual reporting periods beginning after that date. Companies may use either a full retrospective or a modified retrospective approach to adopt the standard. We plan to adopt the new guidance in the first quarter of fiscal 2019 and are currently evaluating the standard, including the method we will use for adoption and the effect it will have on our financial statements. We do not expect the standard to materially affect our consolidated net earnings, financial position, or cash flows. We are currently evaluating the new standard as it relates to certain sales transactions in which products are shipped directly from the vendor to our customers. We currently report these sales on a gross basis, and are evaluating if we will be required to report these sales on a net basis. Such sales represent approximately 2% of our consolidated net sales. Any change to net presentation would not impact gross margin or earnings. In July 2015, the FASB issued ASU No. 2015-11, "Inventory (Topic 330), Simplifying the Measurement of Inventory." ASU 2015-11 requires inventory measured using any method other than LIFO or the retail inventory method to be subsequently measured at the lower of cost or net realizable value, rather than at the lower of cost or market. Subsequent measurement of inventory using the LIFO and retail inventory method is unchanged. During the first quarter of fiscal 2018, we adopted ASU No. 2015-11 and it had no material impact to the condensed consolidated financial statements. In January 2016, the FASB issued ASU No. 2016-01, "Financial Instruments- Recognition and Measurement of Financial Assets and Financial Liabilities (Subtopic 825-10)", which amends certain aspects of recognition, measurement, presentation and disclosure of financial instruments, including the requirement to measure certain equity investments at fair value with changes in fair value recognized in net income. We are required to adopt the ASU No. 2016-01 in the first quarter of fiscal 2019. We are evaluating the impact of adopting this pronouncement. In February 2016, the FASB issued ASU No. 2016-02, "Leases (Topic 842)," which requires lessees to recognize assets and liabilities on the balance sheet for the rights and obligations created by most leases, as well as requires additional qualitative and quantitative disclosures. We are required to adopt ASU 2016-02 in the first quarter of fiscal 2020, with early adoption permitted. We plan to adopt the new guidance in the first quarter of fiscal 2020 and are currently evaluating the impact of adopting this pronouncement. In February 2018, the FASB issued ASU No. 2018-02, "Income Statement-Reporting Comprehensive Income (Topic 220) Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income," which will allow a reclassification from accumulated other comprehensive income to retained earnings for the tax effects that are stranded in accumulated other comprehensive income as a result of tax reform. This standard also requires certain disclosures about stranded tax effects. We are required to adopt ASU No. 2018-02 in the first quarter of fiscal 2020, with early adoption permitted and apply it either in the period of adoption or retrospectively to each period in which the income tax effects of the tax reform related to items in accumulated other comprehensive income are recognized. We are currently evaluating the impact of adopting this pronouncement. |
General (Tables)
General (Tables) | 9 Months Ended |
Jan. 27, 2018 | |
Accounting Policies [Abstract] | |
Computation of Basic and Diluted Earnings Per Share (EPS) | The following table sets forth the computation of the weighted average shares outstanding used to calculate basic and diluted earnings per share ("EPS"): Three Months Ended Nine Months Ended January 27, January 28, January 27, January 28, Denominator for basic earnings per share – weighted average shares 91,949 94,737 92,674 95,252 Effect of dilutive securities – stock options, restricted stock and stock purchase plans 660 622 649 663 Denominator for diluted earnings per share – weighted average shares 92,609 95,359 93,323 95,915 |
Derivative Financial Instrume16
Derivative Financial Instruments (Tables) | 9 Months Ended |
Jan. 27, 2018 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |
Fair Value of Derivative Instruments Included in Condensed Consolidated Balance Sheets | The following presents the fair value of derivative instruments included in the condensed consolidated balance sheets: Derivative type Classification January 27, 2018 April 29, 2017 Assets: Interest rate cap agreements Other noncurrent assets $ 1,061 $ 1,188 Liabilities: Interest rate cap agreements Other noncurrent liabilities 1,061 1,188 |
Effect of Derivative instruments in Cash Flow Hedging Relationship on Condensed Consolidated Statements of Income and Other Comprehensive Income (OCI) | The following table presents the pre-tax effect of derivative instruments in cash flow hedging relationships on the condensed consolidated statements of income and other comprehensive income ("OCI"): Amount of Gain (Loss) Reclassified from Accumulated Other Comprehensive Loss into Income (Effective Portion) Three Months Ended Nine Months Ended Derivatives in cash flow hedging relationships Income statement location January 27, 2018 January 28, 2017 January 27, 2018 January 28, 2017 Interest rate swap Interest expense $ (702 ) $ (702 ) $ (2,107 ) $ (2,099 ) |
Fair Value Measurements (Tables
Fair Value Measurements (Tables) | 9 Months Ended |
Jan. 27, 2018 | |
Fair Value Disclosures [Abstract] | |
Assets and Liabilities Measured at Fair Value on Recurring Basis | Our hierarchy for assets and liabilities measured at fair value on a recurring basis is as follows: January 27, 2018 Total Level 1 Level 2 Level 3 Assets: Cash equivalents $ 3,401 $ 3,401 $ — $ — Deferred purchase price receivable 137,054 — — 137,054 Derivative instruments 1,061 — 1,061 — Total assets $ 141,516 $ 3,401 $ 1,061 $ 137,054 Liabilities: Derivative instruments $ 1,061 $ — $ 1,061 $ — April 29, 2017 Total Level 1 Level 2 Level 3 Assets: Cash equivalents $ 6,798 $ 6,798 $ — $ — Deferred purchase price receivable 119,798 — — 119,798 Derivative instruments 1,188 — 1,188 — Total assets $ 127,784 $ 6,798 $ 1,188 $ 119,798 Liabilities: Derivative instruments $ 1,188 $ — $ 1,188 $ — |
Segment Reporting (Tables)
Segment Reporting (Tables) | 9 Months Ended |
Jan. 27, 2018 | |
Segment Reporting [Abstract] | |
Information about Reportable Segments | The following table presents information about our reportable segments: Three Months Ended Nine Months Ended January 27, January 28, January 27, January 28, Net sales Dental $ 577,877 $ 626,343 $ 1,650,314 $ 1,782,911 Animal Health 794,867 762,577 2,394,586 2,332,354 Corporate 2,478 8,498 20,174 32,830 Consolidated net sales $ 1,375,222 $ 1,397,418 $ 4,065,074 $ 4,148,095 Operating income (loss) from continuing operations Dental $ 58,439 $ 40,018 $ 183,165 $ 177,356 Animal Health 18,037 23,777 57,930 60,460 Corporate (26,430 ) (17,241 ) (62,457 ) (46,043 ) Consolidated operating income from continuing operations $ 50,046 $ 46,554 $ 178,638 $ 191,773 January 27, April 29, Total assets Dental $ 953,273 $ 863,970 Animal Health 2,196,733 2,119,512 Corporate 524,352 524,431 Total assets $ 3,674,358 $ 3,507,913 |
Sales Information by Product | The following table presents sales information by product for all of our reportable segments: Three Months Ended Nine Months Ended January 27, January 28, January 27, January 28, Net sales Consumable $ 1,074,189 $ 1,064,098 $ 3,270,385 $ 3,252,551 Equipment and software 222,574 249,047 540,860 627,187 Other 78,459 84,273 253,829 268,357 Consolidated net sales $ 1,375,222 $ 1,397,418 $ 4,065,074 $ 4,148,095 |
Accumulated Other Comprehensi19
Accumulated Other Comprehensive Loss ("AOCL") (Tables) | 9 Months Ended |
Jan. 27, 2018 | |
Equity [Abstract] | |
Summary of Accumulated Other Comprehensive Loss | The following table summarizes the changes in AOCL as of January 27, 2018 : Cash Flow Hedges Currency Translation Adjustment Total AOCL at April 29, 2017 $ (14,989 ) $ (77,680 ) $ (92,669 ) Other comprehensive loss before reclassifications — 24,594 24,594 Amounts reclassified from AOCL 1,312 — 1,312 AOCL at January 27, 2018 $ (13,677 ) $ (53,086 ) $ (66,763 ) |
General - Additional Informatio
General - Additional Information (Detail) - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Jan. 27, 2018 | Jan. 28, 2017 | Jan. 27, 2018 | Jan. 28, 2017 | |
Accounting Policies [Abstract] | ||||
Income tax expense related to cash flow hedges | $ 265 | $ 265 | $ 795 | $ 792 |
Securities excluded from calculation of diluted earnings per share (in shares) | 1,568 | 1,499 | 1,354 | 1,261 |
General - Computation of Basic
General - Computation of Basic and Diluted Earnings Per Share (EPS) (Detail) - shares shares in Thousands | 3 Months Ended | 9 Months Ended | ||
Jan. 27, 2018 | Jan. 28, 2017 | Jan. 27, 2018 | Jan. 28, 2017 | |
Earnings Per Share [Abstract] | ||||
Denominator for basic earnings per share – weighted average shares (in shares) | 91,949 | 94,737 | 92,674 | 95,252 |
Effect of dilutive securities - stock options, restricted stock and stock purchase plans (in shares) | 660 | 622 | 649 | 663 |
Denominator for diluted earnings per share – weighted average shares (in shares) | 92,609 | 95,359 | 93,323 | 95,915 |
Customer Financing (Detail)
Customer Financing (Detail) | 3 Months Ended | 9 Months Ended | ||||
Jan. 27, 2018USD ($) | Jan. 28, 2017USD ($) | Jan. 27, 2018USD ($)finance_agreement | Jan. 28, 2017USD ($) | Apr. 29, 2017USD ($) | Apr. 30, 2016USD ($) | |
Customer Financing [Line Items] | ||||||
Maximum credit financed for equipment purchases for any one customer | $ 1,000,000 | $ 1,000,000 | ||||
Number of customer financing contracts | finance_agreement | 2 | |||||
Financing contracts sold under ASC 860 | 45,361,000 | $ 106,272,000 | $ 197,072,000 | $ 278,529,000 | ||
Revenues from Sale of Financing Contracts | (1,688,000) | 2,450,000 | 8,539,000 | 16,966,000 | ||
Cash and cash equivalents | 118,005,000 | $ 121,739,000 | 118,005,000 | $ 121,739,000 | $ 94,959,000 | $ 137,453,000 |
Current receivables of finance contracts not yet sold | 114,521,000 | 114,521,000 | 124,098,000 | |||
Unearned income | 0 | 0 | 940,000 | |||
Finance contracts receivable sold and outstanding | 581,291,000 | 581,291,000 | ||||
Deferred purchase price | 137,054,000 | $ 137,054,000 | 119,798,000 | |||
Bad debt write-offs, percentage (less than) | 1.00% | |||||
Unsettled Financing Arrangements | ||||||
Customer Financing [Line Items] | ||||||
Cash and cash equivalents | 36,009,000 | $ 36,009,000 | $ 17,902,000 | |||
The Bank of Tokyo-Mitsubishi UFJ, Ltd. | ||||||
Customer Financing [Line Items] | ||||||
Percentage of principal amount of financing contracts held as collateral (at least) | 9.50% | |||||
Capacity under agreement | 575,000,000 | $ 575,000,000 | ||||
Fifth Third Bank | ||||||
Customer Financing [Line Items] | ||||||
Percentage of principal amount of financing contracts held as collateral (at least) | 11.00% | |||||
Capacity under agreement | $ 100,000,000 | $ 100,000,000 |
Derivative Financial Instrume23
Derivative Financial Instruments - Additional Information (Detail) | Mar. 25, 2015USD ($) | Mar. 31, 2015USD ($) | Jan. 31, 2014USD ($) | Mar. 31, 2008USD ($)agreement | Jan. 27, 2018USD ($) | Jan. 28, 2017USD ($) | Jan. 27, 2018USD ($) | Jan. 28, 2017USD ($) |
Derivative [Line Items] | ||||||||
Effective portion of gains or losses recognized in OCI | $ 0 | |||||||
Ineffectiveness recorded during period | $ 0 | $ 0 | 0 | $ 0 | ||||
Increase (decrease) in interest expense | (2,885,000) | |||||||
Interest Rate Cap | ||||||||
Derivative [Line Items] | ||||||||
Notional amount of derivatives | 575,000,000 | 575,000,000 | ||||||
New Interest Rate Cap | ||||||||
Derivative [Line Items] | ||||||||
Notional amount of derivatives | 100,000,000 | 100,000,000 | ||||||
Interest Rate Swap | ||||||||
Derivative [Line Items] | ||||||||
Number of interest rate swap agreements | agreement | 2 | |||||||
Notional amount of derivative asset | $ 100,000,000 | |||||||
Increase to other comprehensive income | 1,000,000 | |||||||
Increase (decrease) in interest expense | $ (702,000) | $ (702,000) | $ (2,107,000) | $ (2,099,000) | ||||
Interest Rate Swap Two | ||||||||
Derivative [Line Items] | ||||||||
Notional amount of derivative asset | $ 100,000,000 | |||||||
Interest Rate Swap Agreement | ||||||||
Derivative [Line Items] | ||||||||
Settlement of swap | $ 29,003,000 | |||||||
Interest Rate Swap Agreement | 5.17% Senior Notes | ||||||||
Derivative [Line Items] | ||||||||
Notional amount of derivatives | $ 250,000,000 | |||||||
Percentage of senior notes | 5.17% | |||||||
Maturity date of long-term loan | Mar. 25, 2015 | |||||||
Interest Rate Swap Agreement | Senior Notes 3.48% | ||||||||
Derivative [Line Items] | ||||||||
Percentage of senior notes | 3.48% | |||||||
Maturity date of long-term loan | Mar. 24, 2025 | |||||||
Aggregate principal amount | $ 250,000,000 |
Derivative Financial Instrume24
Derivative Financial Instruments - Fair Value of Derivative Instruments Included in Condensed Consolidated Balance Sheets (Detail) - USD ($) $ in Thousands | Jan. 27, 2018 | Apr. 29, 2017 |
Derivatives, Fair Value [Line Items] | ||
Interest rate contracts, assets, fair value | $ 1,061 | $ 1,188 |
Interest rate contracts, liabilities, fair value | 1,061 | 1,188 |
Other Noncurrent Assets | Interest Rate Contracts | ||
Derivatives, Fair Value [Line Items] | ||
Interest rate contracts, assets, fair value | 1,061 | 1,188 |
Other Noncurrent Liabilities | Interest Rate Contracts | ||
Derivatives, Fair Value [Line Items] | ||
Interest rate contracts, liabilities, fair value | $ 1,061 | $ 1,188 |
Derivative Financial Instrume25
Derivative Financial Instruments - Effect of Derivative Instruments in Cash Flow Hedging Relationships on Condensed Consolidated Statements of Income and Other Comprehensive Income (OCI) (Detail) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Jan. 27, 2018 | Jan. 28, 2017 | Jan. 27, 2018 | Jan. 28, 2017 | |
Derivative Instruments, Gain (Loss) [Line Items] | ||||
Accumulated other comprehensive loss expected to be reclassified into earnings | $ (2,885) | |||
Interest Rate Swap | ||||
Derivative Instruments, Gain (Loss) [Line Items] | ||||
Accumulated other comprehensive loss expected to be reclassified into earnings | $ (702) | $ (702) | $ (2,107) | $ (2,099) |
Fair Value Measurements - Asset
Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands | Jan. 27, 2018 | Apr. 29, 2017 |
Assets: | ||
Cash equivalents | $ 3,401 | $ 6,798 |
Deferred purchase price receivable | 137,054 | 119,798 |
Derivative instruments | 1,061 | 1,188 |
Total assets | 141,516 | 127,784 |
Liabilities: | ||
Derivative instruments | 1,061 | 1,188 |
Fair Value, Inputs, Level 1 | ||
Assets: | ||
Cash equivalents | 3,401 | 6,798 |
Deferred purchase price receivable | 0 | 0 |
Derivative instruments | 0 | 0 |
Total assets | 3,401 | 6,798 |
Liabilities: | ||
Derivative instruments | 0 | 0 |
Fair Value, Inputs, Level 2 | ||
Assets: | ||
Cash equivalents | 0 | 0 |
Deferred purchase price receivable | 0 | 0 |
Derivative instruments | 1,061 | 1,188 |
Total assets | 1,061 | 1,188 |
Liabilities: | ||
Derivative instruments | 1,061 | 1,188 |
Fair Value, Inputs, Level 3 | ||
Assets: | ||
Cash equivalents | 0 | 0 |
Deferred purchase price receivable | 137,054 | 119,798 |
Derivative instruments | 0 | 0 |
Total assets | 137,054 | 119,798 |
Liabilities: | ||
Derivative instruments | $ 0 | $ 0 |
Fair Value Measurements - Addit
Fair Value Measurements - Additional Information (Detail) - USD ($) $ in Thousands | Jan. 27, 2018 | Apr. 29, 2017 |
Fair Value Disclosures [Abstract] | ||
Estimated fair value of debt | $ 1,013,300 | $ 1,025,761 |
Carrying value of debt | $ 1,006,173 | $ 1,013,026 |
Income Taxes (Detail)
Income Taxes (Detail) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||
Jan. 27, 2018 | Jan. 28, 2017 | Jan. 27, 2018 | Jan. 28, 2017 | Apr. 28, 2018 | |
Income Tax Disclosure [Abstract] | |||||
Effective income tax rate | (170.00%) | 23.20% | (20.90%) | 31.90% | |
Income Tax [Line Items] | |||||
Tax Cuts And Jobs Act Of 2017,incomplete accounting, provisional income tax benefit | $ 77,256 | ||||
Tax Cuts And Jobs Act Of 2017, incomplete accounting, change in tax rate, deferred taxes, provisional income tax expense | 81,206 | ||||
Tax Cuts And Jobs Act Of 2017, incomplete accounting, transition tax for unremitted foreign earnings | $ (3,950) | ||||
Scenario, Forecast | |||||
Income Tax [Line Items] | |||||
Blended income tax rate, percent | 30.50% |
Intangible Asset Impairment (De
Intangible Asset Impairment (Detail) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended |
Jan. 28, 2017 | Dec. 31, 2006 | |
Goodwill and Intangible Assets Disclosure [Abstract] | ||
Distribution fee paid | $ 100,000 | |
Distribution relationship term extension | 10 years | |
Distribution Rights | Dental | ||
Finite-Lived Intangible Assets [Line Items] | ||
Impairment charge | $ 36,312 |
Segment Reporting - Narrative (
Segment Reporting - Narrative (Detail) | 6 Months Ended |
Oct. 28, 2017Segment | |
Segment Reporting [Abstract] | |
Number of reportable segments | 3 |
Segment Reporting - Information
Segment Reporting - Information about Reportable Segments (Detail) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | 9 Months Ended | ||||||
Jan. 27, 2018 | Oct. 28, 2017 | Jan. 28, 2017 | Oct. 29, 2016 | Oct. 28, 2017 | Oct. 29, 2016 | Jan. 27, 2018 | Jan. 28, 2017 | Apr. 29, 2017 | |
Segment Reporting Information [Line Items] | |||||||||
Net sales | $ 1,375,222 | $ 1,375,222 | $ 1,397,418 | $ 1,397,418 | $ 4,065,074 | $ 4,148,095 | $ 4,065,074 | $ 4,148,095 | |
Operating income (loss) from continuing operations | 50,046 | 46,554 | 178,638 | 191,773 | |||||
Total assets | 3,674,358 | 3,674,358 | $ 3,507,913 | ||||||
Operating Segments | Dental | |||||||||
Segment Reporting Information [Line Items] | |||||||||
Net sales | 577,877 | 626,343 | 1,650,314 | 1,782,911 | |||||
Operating income (loss) from continuing operations | 58,439 | 40,018 | 183,165 | 177,356 | |||||
Total assets | 953,273 | 953,273 | 863,970 | ||||||
Operating Segments | Animal Health | |||||||||
Segment Reporting Information [Line Items] | |||||||||
Net sales | 794,867 | 762,577 | 2,394,586 | 2,332,354 | |||||
Operating income (loss) from continuing operations | 18,037 | 23,777 | 57,930 | 60,460 | |||||
Total assets | 2,196,733 | 2,196,733 | 2,119,512 | ||||||
Operating Segments | Corporate | |||||||||
Segment Reporting Information [Line Items] | |||||||||
Net sales | 2,478 | 8,498 | 20,174 | 32,830 | |||||
Operating income (loss) from continuing operations | (26,430) | $ (17,241) | (62,457) | $ (46,043) | |||||
Total assets | $ 524,352 | $ 524,352 | $ 524,431 |
Segment Reporting - Sales Infor
Segment Reporting - Sales Information by Product (Detail) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | 9 Months Ended | |||||
Jan. 27, 2018 | Oct. 28, 2017 | Jan. 28, 2017 | Oct. 29, 2016 | Oct. 28, 2017 | Oct. 29, 2016 | Jan. 27, 2018 | Jan. 28, 2017 | |
Segment Reporting Information [Line Items] | ||||||||
Net sales | $ 1,375,222 | $ 1,375,222 | $ 1,397,418 | $ 1,397,418 | $ 4,065,074 | $ 4,148,095 | $ 4,065,074 | $ 4,148,095 |
Consumable | ||||||||
Segment Reporting Information [Line Items] | ||||||||
Net sales | 1,074,189 | 1,064,098 | 3,270,385 | 3,252,551 | ||||
Equipment and software | ||||||||
Segment Reporting Information [Line Items] | ||||||||
Net sales | 222,574 | 249,047 | 540,860 | 627,187 | ||||
Other | ||||||||
Segment Reporting Information [Line Items] | ||||||||
Net sales | $ 78,459 | $ 84,273 | $ 253,829 | $ 268,357 |
Accumulated Other Comprehensi33
Accumulated Other Comprehensive Loss ("AOCL") - Summary of Accumulated Other Comprehensive Loss (Detail) $ in Thousands | 9 Months Ended |
Jan. 27, 2018USD ($) | |
AOCI Attributable to Parent, Net of Tax [Roll Forward] | |
AOCL Beginning Balance | $ 1,394,433 |
AOCL Ending Balance | 1,462,990 |
Cash Flow Hedges | |
AOCI Attributable to Parent, Net of Tax [Roll Forward] | |
AOCL Beginning Balance | (14,989) |
Other comprehensive loss before reclassifications | 0 |
Amounts reclassified from AOCL | 1,312 |
AOCL Ending Balance | (13,677) |
Currency Translation Adjustment | |
AOCI Attributable to Parent, Net of Tax [Roll Forward] | |
AOCL Beginning Balance | (77,680) |
Other comprehensive loss before reclassifications | 24,594 |
Amounts reclassified from AOCL | 0 |
AOCL Ending Balance | (53,086) |
Total | |
AOCI Attributable to Parent, Net of Tax [Roll Forward] | |
AOCL Beginning Balance | (92,669) |
Other comprehensive loss before reclassifications | 24,594 |
Amounts reclassified from AOCL | 1,312 |
AOCL Ending Balance | $ (66,763) |
Accumulated Other Comprehensi34
Accumulated Other Comprehensive Loss ("AOCL") - Additional Information (Detail) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Jan. 27, 2018 | Jan. 28, 2017 | Jan. 27, 2018 | Jan. 28, 2017 | |
Equity [Abstract] | ||||
Income tax expense related to cash flow hedges | $ 265 | $ 265 | $ 795 | $ 792 |
Increase in interest expense | $ 2,107 |